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sis through prostaglandin E2 (PGE2) biosynthesis. It has been
shown by in vitro studies that PGE2 signaling transactivates epi-
dermal growth factor receptor (EGFR) through an intracellular
mechanism. However, the mechanisms underlying PGE2-induced
EGFR activation in in vivo tumors are still not fully understood. We
previously constructed transgenic mice that develop gastric
tumors caused by oncogenic activation and PGE2 pathway induc-
tion. Importantly, expression of EGFR ligands, epiregulin, amphi-
regulin, heparin-binding EGF-like growth factor, and betacellulin,
as well as a disintegrin and metalloproteinases (ADAMs), ADAM8,
ADAM9, ADAM10, and ADAM17 were significantly increased in
the mouse gastric tumors in a PGE2 pathway-dependent manner.
These ADAMs can activate EGFR by ectodomain shedding of EGFR
ligands. Notably, the extensive induction of EGFR ligands and
ADAMs was suppressed by inhibition of the PGE2 receptor EP4.
Moreover, EP4 signaling induced expression of amphiregulin and
epiregulin in activated macrophages, whereas EP4 pathway was
required for basal expression of epiregulin in gastric epithelial
cells. In contrast, ADAMs were not induced directly by PGE2 in
these cells, suggesting indirect mechanism possibly through PGE2-
associated inflammatory responses. These results suggest that
PGE2 signaling through EP4 activates EGFR in gastric tumors
through global induction of EGFR ligands and ADAMs in several
cell types either by direct or indirect mechanism. Importantly, gas-
tric tumorigenesis of the transgenic mice was significantly sup-
pressed by combination treatment with EGFR and COX-2
inhibitors. Therefore, it is possible that inhibition of both COX-
2 ⁄ PGE2 and EGFR pathways represents an effective strategy for
preventing gastric cancer. (Cancer Sci 2011; 102: 713–719)
I t has been established that induction of cyclooxygenase 2(COX-2) plays an important role in cancer development.(1,2)
Genetic mouse model studies indicated that prostaglandin E2
(PGE2), a downstream products of COX-2, plays a key role in
intestinal tumorigenesis,(3–5) suggesting that the PGE2 pathway
is a possible target for the chemoprevention. On the other hand,
epidermal growth factor receptor (EGFR) signaling is also an
important target for cancer prevention.(6) Inhibition of EGFR
signaling in ApcMin mice, a model of familial adenomatous
polyposis, significantly suppresses intestinal polyposis.(7–9)
Importantly, combination treatment using an EGFR inhibitor
with non-steroidal anti-inflammatory drugs or a COX-2 inhibitor
dramatically suppresses intestinal tumorigenesis.(8,9) It has
been shown by in vitro experiments that PGE2 signaling trans-
activates EGFR through activation of cSrc(10,11) or MMPs(12), as
well as induction of amphiregulin, an EGFR ligand(13,14) or
tumor necrosis factor-a converting enzyme ⁄ a disintegrin and
metalloproteinase 17 (TACE/ADAM17), a shedding enzyme for
amphiregulin.(15) However, the mechanism responsible for thedoi: 10.1111/j.1349-7006.2011.01847.x
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not been fully elucidated. Induction of the PGE2 pathway in the
gastric mucosa causes development of inflammatory microenvi-
ronment consisting of macrophages and myofibroblasts.(16,17) It
is therefore possible that PGE2 signaling in such microenviron-
ment contributes to EGFR activation in tumors, and that PGE2-
associated inflammatory responses are also involved in EGFR
activation.
Gastric cancer is one of the most frequently diagnosed and
lethal malignancies worldwide, with a 5-year survival of only
about 20%.(18) COX-2 expression is induced in more than 70%
of gastric cancers,(19) and regular use of non-steroidal anti-
inflammatory drugs decreases the risk of gastric cancer,(20) sug-
gesting a role of COX-2 pathway in gastric tumorigenesis. In
addition to COX-2, activation of Wnt signaling is found in 30–
50% of gastric cancers.(21,22) Based on these results, we con-
structed K19-Wnt1 ⁄C2mE transgenic mice expressing Wnt1,
Ptgs2, and Ptges encoding Wnt1, COX-2, and microsomal
prostaglandin E synthase-1, respectively, in gastric mucosa.(22)
K19-Wnt1 ⁄C2mE mice (Gan mice for gastric neoplasia) develop
gastric tumors caused by the simultaneous activation of Wnt and
PGE2 pathways, although Wnt activation alone results in the
development of only small dysplastic lesions. Gene expression
profiles of Gan mouse tumors were similar to those of human
intestinal-type gastric cancer.(23) We also constructed K19-
Nog ⁄C2mE transgenic mice that express Nog encoding noggin,
together with Ptgs2 and Ptges.(24) Noggin is an endogenous
antagonist for bone morphogenetic protein signaling. K19-
Nog ⁄C2mE mice develop gastric hamartomas, although Nog
expression alone does not cause any morphological changes.
These results indicate that induction of the PGE2 pathway plays
a key role in the promotion of gastric tumorigenesis, regardless
of the types of underlying oncogenic pathway such as Wnt acti-
vation or bone morphogenetic protein suppression.(25)
Using these mouse models, we have investigated the mecha-
nism of EGFR activation by the PGE2 pathway in gastric tumor-
igenesis. We also examined the role of EGFR signaling in the
in vivo tumor development by drug dosing experiments.
Materials and Methods
Mouse models. Construction of K19-Wnt1, K19-C2mE, K19-
Nog, K19-Wnt1 ⁄C2mE (Gan), and K19-Nog ⁄C2mE mice was
described previously.(25) Briefly, both Ptgs2 and Ptges are
expressed in the K19-C2mE mouse stomach, whereas Wnt1 and
Nog are expressed in K19-Wnt1 and K19-Nog mice, respec-
tively. Expression of these genes is regulated by the Krt19 gene
promoter that is transcriptionally active in gastric epithelial
cells. Gan mice and K19-Nog ⁄C2mE mice were obtained byCancer Sci | April 2011 | vol. 102 | no. 4 | 713–719
Table 1. Transgenic mouse models and their gastric phenotypes
Transgenic mice Transgenes Affected pathway(s) Gastric phenotype (reference)
K19-C2mE Ptgs2, Ptges PGE2 induction Inflammation, hyperplasia
(16,25)
K19-Wnt1 Wnt1 Wnt activation Small dysplastic lesion(22,25)
K19-Nog Nog BMP suppression No phenotype(24,25)
K19-Wnt1 ⁄ C2mE (Gan) Wnt1, Ptgs2, Ptges Wnt activation ⁄ PGE2 induction Dysplastic tumor(22,25)
K19-Nog ⁄ C2mE Nog, Ptgs2, Ptges BMP suppression ⁄ PGE2 induction Hamartoma(24,25)
BMP, bone morphogenetic protein.crossing K19-C2mE with K19-Wnt1 or K19-Nog, respectively
(Table 1). All animal experiments were carried out according to
a protocol approved by the Committee on Animal Experimenta-
tion of Kanazawa University.
Microarray analyses. We have deposited the results of micro-
array data sets from a series of mouse models to the Gene
Expression Omnibus, as accession GSE16902.(23) Expression
profiles of EGFR ligands, EGFR family members, and ADAM
family proteases were extracted from the data sets, and the
expression levels were compared by using absolute values.
Drug administration. For inhibition of COX-2, mice were fed
a diet containing celecoxib (Pfizer New York, NY, USA) at
1500 ppm. For inhibition of EGFR or EP4 receptor, mice were
administered orally with ZD1839 (Astra Zeneca, London, UK)
or RQ00015986 ⁄CJ-42794(26) (RaQualia, Taketoyo, Japan),
respectively, at 100 mg ⁄kg ⁄day in 0.5% methylcellulose. Drug-
dosing experiments using Gan mice were performed for 3 weeks
from 47 weeks of age (n = 5 for each experiment). The relative
gastric tumor volume was calculated by multiplication of
tumor height and tumor area measured using the ImageJ applica-
tion program (NIH, Bethesda, MD, USA). X-ray computed
tomography images of gastric tumors in live mice were exam-
ined using LaTheta LCT-100 (Aloka, Tokyo, Japan) at weeks 0,
1, 2 and 3 of drug administration.
Reverse transcription-polymerase chain reaction. Total RNA
was extracted from mouse stomach or cultured cells using ISO-
GEN (Nippon Gene, Tokyo, Japan). Extracted RNA was
reverse-transcribed with a PrimeScript RT reagent kit (Takara,
Tokyo, Japan) and PCR-amplified by ABI prism 7900HT
(Applied Biosystems, Carlsbad, CA, USA) using SYBR Premix
Ex Taq II (Takara). Primers for real-time RT-PCR were pur-
chased (Takara).
Cell Culture experiments. Mouse macrophage RAW264 cells
(RIKEN BioRessource Center, Tsukuba, Japan) were cultured in
RPMI1640, and treated with lipopolysaccharide (LPS) (Sigma,
St. Louis, MO, USA) at 100 ng ⁄mL with or without treatment
of celecoxib or RQ00015986 at 10 lM for 24 h. Medium con-
centration of amphiregulin was measured by using Mouse
Amphiregulin ELISA kit (RayBiotech, Norcross, GA, USA).
Knockdown of Adam8 expression was performed using Adam8
ON-TARGETplus SMARTpool siRNA reagents (Dharmacon,
Boulder, CO, USA). For the primary culture of gastric epithelial
cells, glandular stomachs of K19-Wnt1 mice were treated with
0.1% collagenase for 45 min followed by trypsin digestion, and
cells were cultured in matrigel (BD Biosciences, Franklin Lakes,
NJ, USA) with the primary culture medium with or without
1 lg ⁄mL EGF (BD Biosciences)(16) supplemented with
500 ng ⁄mL R-spondin1 (R&D, Mineapolis, MN, USA), 1 lM
of Jagged1 (AnaSpec, Fremont, CA, USA), and 100 ng ⁄mL of
Noggin (PeproTech, Rocky Hill, NJ, USA). The primary cul-
tured cells were stimulated with mouse recombinant amphiregu-
lin and epiregulin (R&D) at 20 and 1 ng ⁄mL, respectively, and
the mean number of cystic structures >75 lm in diameter per
microscopic field was calculated at day 5.
Immunoblotting analysis. Tissue samples were homogenized
and sonicated in lysis buffer. After centrifugation at 2000g,
10 lg of the supernatant protein was separated in a 10%714SDS-polyacrylamide gel. Antibodies for phosphorylated Akt
(Ser473) and phosphorylated p44 ⁄42 Erk1 ⁄2 (cell signaling)
were used as the primary antibodies. b-Actin was used as an
internal control. The ECL detection system (GE Healthcare,
Buckinghamshire, UK) was used to detect specific signals. The
band intensities were measured using the ImageJ application
(NIH).
Histology and immunohistochemistry. Tissues and the pri-
mary cultured cells were paraffin-embedded or frozen in OCT
compound (Sakura Finetechnical, Tokyo, Japan), and sectioned.
These sections were stained with H&E or processed for immu-
nostaining. Antibody for phosphorylated EGFR (Tyr845) (cell
signaling), Ki-67 (DakoCytomation, Carpenteria, CA, USA), or
active b-catenin (Millipore, Billerica, MA, USA) was used as
the primary antibody. Immunostaining signals were visualized
using the Vectastain Elite kit (Vector Laboratories, Burlingame,
CA, USA). For fluorescence immunostaining, anti-rabbit IgG
Alexa 488 (Molecular Probes, Eugene, OR, USA) was used for
the secondary antibody. The mean Ki-67 labeling index of the
five independent microscopic fields was calculated.
Statistical analysis. Statistical analyses were performed using
the unpaired Student’s t-test, with P-values <0.05 considered
significant.
Results
Induction of EGFR ligands and ADAM proteases in gastric
tumors by PGE2 pathway. We examined gene expression pro-
files of EGFR ligands and EGFR members in the stomach or
gastric tumors of the all mouse models listed in Table 1. Among
these models, PGE2 pathway is induced in the stomach of K19-
C2mE, Gan, and K19-Nog ⁄C2mE mice by expression of Ptgs2
and Ptges. Hereafter, these three strains are termed the C2mE
group. Interestingly, expression of amphiregulin (Areg), epireg-
ulin (Ereg), HB-EGF (Hbegf), and betacellulin (Btc), as well as
Her2 (Erbb2), and Her3 (Erbb3) increased significantly in the
stomach of the C2mE group mice (Fig. 1a). In contrast, such
induction was not observed in the stomach of K19-Wnt1 and
K19-Nog mice, indicating that induction of PGE2 pathway is
responsible for upregulation of these genes.
ADAMs activate EGFR signaling through ectodomain shed-
ding of EGFR ligands, and are induced in a variety of cancer
tissues.(27) Notably, expression of Adam8, Adam9, Adam10,
Adam17, and Adam28 was increased significantly in the stomach
of the C2mE group mice but not in other strains, indicating the
PGE2 pathway-dependent induction of these ADAMs (Fig. 1b).
It has been shown that ADAM8, ADAM 10 and ADAM17 can
cleave and activate amphiregulin, epiregulin, HB-EGF, or beta-
cellulin.(28–30) It is thus possible that EGFR is activated in the
gastric mucosa of C2mE group mice through induction of both
EGFR ligands and ADAM proteases. Induction of Erbb2 may
also contribute to EGFR activation by increasing the heterodi-
merization of EGFR and HER2. Consistently, the immunostain-
ing intensity of phosphorylated EGFR increased significantly in
the gastric epithelial cells of K19-C2mE and Gan mice but not
in those of WT and K19-Wnt1 mice, indicating PGE2 pathway-
dependent EGFR activation (Fig. 1c).doi: 10.1111/j.1349-7006.2011.01847.x
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(a)
(b) (c)
Fig. 1. Gene expression levels of epidermal growth
factor receptor (EGFR) ligands, EGFR family members
(a) and a disintegrin and metalloproteinases
(ADAMs) (b) in the stomach of the respective models
(mean ± SD) calculated from microarray results.
Asterisks indicate P < 0.05 versus the wild-type level.
(c) Fluorescence immunostaining for phosphorylated
EGFR at Tyr845 (green) in the gastric mucosa of the
indicated genotype mice. DAPI staining for nuclei is
visualized in red. Bars indicate 100 lm.Induction of EGFR ligands and ADAM proteases by PGE2
receptor EP4 signaling. We next treated Gan mice with a
COX-2 inhibitor, celecoxib, and found that expression of Areg,
Ereg, Hbegf, and Btc as well as Adam8, Adam9, Adam10,
Adam17 and Adam28 in gastric tumors decreased significantly
(Fig. 2a). Among the four PGE2 receptors, EP1-EP4, expression
of EP4 was significantly increased in gastric tumors of C2mE
group mice.(24) We thus treated Gan mice with an EP4-specific
inhibitor, RQ00015986. Importantly, inhibition of the EP4
receptor caused a decrease in the expression of these EGFR
ligands and ADAMs to a similar level to that in the celecoxib-
treated mice (Fig. 2a). These results indicate that PGE2 signal-
ing through EP4 is required for induction of EGFR ligands and
ADAMs in gastric tumor tissues.
Induction of EGFR ligands by EP4 signaling in activated
macrophages. Macrophages are infiltrated in the gastric mucosa
in the C2mE group mice,(16,22) and tumor-associated macrophag-
es play an important role in tumorigenesis through expression of
growth factors.(31) We thus examined induction of EGFR ligands
and ADAMs in macrophages using the RAW264 cells. Stimula-
tion of macrophages with LPS induced expression of Ptgs2 and
Ptges, resulting in an increased PGE2 level in the cell culture med-
ium (Fig. 2b and not shown). In the LPS-activated macrophages,
expression of Areg, Ereg, and Hbegf, as well as Adam8 increased
significantly, while expression of other ADAM members did not
(Fig. 2b,c). Notably, inhibition of COX-2 or the EP4 receptor by
treatment with celecoxib or RQ00015986, respectively, signifi-
cantly suppressed induction of Areg and Ereg in the LPS-stimu-
lated macrophages. These results suggest that EP4 signaling
induces expression of Areg and Ereg in the activated macrophag-
es in an autocrine or paracrine manner. In contrast, expression ofOshima et al.Hbegf and Adam8 was not decreased by inhibition of COX-2 or
EP4, suggesting that other factors from activated macrophages
induced these genes. Expression of Btc was not detected in the
LPS-stimulated or control RAW264 cells (data not shown).
We confirmed that medium concentration of the cleaved
amphiregulin increased significantly in the LPS-stimulated
RAW264 cells (Fig. 2d). To examine the role of Adam8 in shed-
ding of amphiregulin, we used Adam8 siRNA that successfully
decreased Adam8 mRNA level in macrophages (Fig. 2e). Impor-
tantly, transfection of Adam8 siRNA reduced amphiregulin con-
centration significantly (Fig. 2d). These results indicate that LPS
stimulation induces amphiregulin secretion from macrophages
through induction of Areg and Adam8 in a PGE2-dependent and
independent mechanisms.
Basal epiregulin expression by EP4 signaling in gastric
epithelial cells. To examine gene expression in gastric epithelial
cells, we established the primary culture system in matrigel.
Although gastric epithelial cells from WT mice proliferated for
3–5 days in matrigel forming small cystic structures (Fig. 3a),
they could not continue proliferation. In contrast, gastric epithe-
lial cells from K19-Wnt1 transgenic mice continued proliferation
in matrigel forming large cystic structures. These structures con-
sisted of monolayer of epithelial cells with nuclear accumulation
of b-catenin (Fig. 3b), suggesting that Wnt activation increases
self-renewal activity of gastric epithelial cells. Expression of
EGFR ligands and ADAMs was not increased by PGE2 stimula-
tion in the primary cultured epithelial cells. However, EP4 inhi-
bition resulted in a significant decrease of Ereg expression level,
suggesting that EP4 signaling is required for basal expression
of Ereg (Fig. 3c). Expression of Hbegf was not detected in the
gastric epithelial cells (data not shown).Cancer Sci | April 2011 | vol. 102 | no. 4 | 715






Fig. 2. (a) The mRNA levels of epidermal growth
factor receptor (EGFR) ligands and a disintegrin and
metalloproteinases (ADAMs) examined by real-time
RT-PCR in gastric tumors of celecoxib-treated or
RQ00015986-treated Gan mice relative to the
no-drug control Gan mouse level (mean ± SD).
Asterisks indicate P < 0.05 versus the control level.
(b) The mRNA levels of Ptgs2, Ptges, and EGFR
ligands in the control and the drug-treated
lipopolysaccharide (LPS)-stimulated RAW264 cells
relative to that of LPS-stimulated RAW264 cells
(mean ± SD). Asterisks indicate P < 0.05 versus the
level of LPS-stimulated cells. (c) The mRNA levels of
Adams in no-drug and drug-treated LPS-stimulated
RAW264 cells relative to that of control RAW264
cells (mean ± SD). Asterisk indicates P < 0.05 versus
the level of LPS-stimulated cells. (d) Concentration
of amphiregulin in the culture medium of the LPS-
stimulated and Adam8 siRNA-transfected RAW264
cells relative to that of LPS-stimulated RAW264 cells
(mean ± SD). Asterisk indicates P < 0.05. (e) The
Adam8 mRNA level in the Adam8 siRNA-transfected
RAW264 cells relative to that of control cells (cont)
(mean ± SD). Asterisk indicates P < 0.05. [Correction
added after online publication on March 18, 2011.
Areg mRNA is changed to Adam8 on Fig. 2(e).]Notably, stimulation of the gastric epithelial cells either by
amphiregulin or epiregulin increased the size of cystic structures
in matrigel, indicating that these EGFR ligands accelerate prolif-
eration of gastric epithelial cells (Fig. 3d). These results support
the idea that induction of amphiregulin and epiregulin by PGE2
pathway promotes gastric tumorigenesis through activation of
epithelial EGFR.
Suppression of Gan mouse gastric tumorigenesis by EGFR
inhibition. Treatment of Gan mice with celecoxib decreased
gastric tumor volume to 10.2% of the no-drug control mice, con-
firming that COX-2 pathway is important for gastric tumorigen-
esis (Fig. 4a,b). Importantly, treatment of Gan mice with an
EGFR inhibitor, ZD1839, also reduced the gastric tumor volume
to 23.6% of the control mice. Moreover, combination treatment
with ZD1839 and celecoxib resulted in complete regression of
Gan mouse gastric tumors. We confirmed the dramatic regres-
sion of gastric tumors by combination therapy with celecoxib
and ZD1839 in the same mice by chronological examinations
using X-ray computed tomography (Fig. 4c). The transgenic
expression of Ptgs2 and Wnt1 in the ZD1839-treated Gan mice
stayed at a similarly high level as that in the control Gan mice
(Fig. 4d). On the other hand, expression of Ptges decreased sig-
nificantly by ZD1839 treatment, suggesting that endogenous
Ptges was induced by activation of EGFR signaling in gastric
tumors. However, Ptges expression level in the ZD1839-treated716Gan mice was still at the high level compared with WT mice.
These results collectively indicate that EGFR activation is
required for gastric tumorigenesis, even if the Wnt and PGE2
pathways are activated.
Suppression of tumor cell proliferation by EGFR inhibition.
Two major pathways downstream of EGFR signaling are the
MAPK and PI3K ⁄Akt pathways.(32) The levels of phosphory-
lated Akt and Erk1 ⁄2 were significantly decreased by ZD1839
treatment in the Gan mouse gastric tumors (Fig. 5a,b). Notably,
celecoxib treatment also suppressed the phosphorylation of Akt
and Erk1 ⁄2 to a similar level as in the ZD1839-treated mice,
suggesting that induction of PGE2 pathway is a major mecha-
nism for activation of EGFR in gastric tumors.
Most tumor cells were immunostained for Ki-67 in the control
Gan mice, while the number of Ki-67 positive cells was signifi-
cantly decreased both in the ZD1839-treated and celecoxib-
treated mice (Fig. 5c,d). Accordingly, it is possible that the
PGE2 pathway accelerates tumor cell proliferation through
EGFR activation.
Discussion
We found that there was simultaneous gene upregulation of
EGFR ligands, Areg, Ereg, Hbegf and Btc, in the mouse gastric
tumors, which occurred in a PGE2-dependent manner. PGE2doi: 10.1111/j.1349-7006.2011.01847.x
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(a) (b)
(c) (d)
Fig. 3. (a) Representative photographs of the
primary cultured gastric epithelial cells in matrigel
from wild type (left) and K19-Wnt1 mice (right).
Arrowheads indicate cystic structures, while arrows
indicate clusters of dead cells. Bars indicate 500 lm.
(b) Histology (top, H&E) and immunostaining with
anti-active b-catenin antibody (bottom) of cystic
structures. Inset indicates nuclear accumulation
of active b-catenin in the epithelial cells. (c)
Relative expression of epidermal growth factor
receptor (EGFR) ligands and a disintegrin and
metalloproteinases (ADAMs) in gastric epithelial
cells cultured in matrigel with the indicated
treatment (mean ± SD). Asterisk indicates P < 0.05
versus the level in control cells cultured in EGF
()) medium. (d) The mean number of cystic
structures >75 lm in diameter in matrigel of the
amphiregulin-treated (Areg), epiregulin-treated
(Ereg) and control (cont) gastric epithelial cells




Fig. 4. (a) Representative photographs of Gan
mouse stomach; no-drug control (top left),
celecoxib-treated (top right), ZD1839-treated
(bottom left), and treated with a combination of
ZD1839 and celecoxib (bottom right). Arrows
indicate gastric tumors in control mouse, whereas
arrowheads indicate regressed tumors in the drug-
treated mice. (b) Tumor volumes of Gan mice
treated with celecoxib, ZD1839, and a combination
of ZD1839 and celecoxib relative to control mice.
Each filled circle indicates the value of individual
mice, and the means of the respective groups are
indicated. (c) X-ray computed tomography images
of the same Gan mouse treated with a combination
of ZD1839 and celecoxib at weeks 0, 1, 2 and 3
after starting drug administration. Yellow dashed
lines indicate the stomach. Arrows indicate gastric
tumors. (d) The mRNA levels of Ptgs2, Ptges, and
Wnt1 examined by real-time RT-PCR in the gastric
tumors of no-drug control (Cont) and ZD1839-
treated (ZD) Gan mice relative to wild-type level
(wild) (mean ± SD). Asterisks indicate P < 0.05
versus wild-type level.signaling through the EP4 receptor is required for basal expres-
sion of Ereg in epithelial cells, whereas both Areg and Ereg are
induced by EP4 signaling in macrophages. On the other hand,
Hbegf is induced in the activated macrophages in a PGE2-inde-
pendent manner. Accordingly, it is possible that expression ofOshima et al.the respective EGFR ligands is regulated not only by PGE2 sig-
naling but also by PGE2-induced inflammation in the different
cell types including macrophages and epithelial cells.
It has been reported that PGE2 signaling activates MMPs and
ADAM17, resulting in shedding of TGF-a or amphiregulin,Cancer Sci | April 2011 | vol. 102 | no. 4 | 717
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(c) (d)
Fig. 5. (a) Western blotting of phosphorylated Akt
and phosphorylated Erk1 ⁄ 2 in gastric tumors of
two independent no-drug control, ZD1839-treated,
and celecoxib-treated Gan mice. b-Actin was used
as an internal control. (b) Relative band intensities
of Western blotting results to the control level
(mean ± SD). Asterisks indicate P < 0.05 versus the
control level. (c) Immunostaining for Ki-67 of
gastric tumors. Bars indicate 100 lm. (d) Ki-67
labeling index of ZD1839-treated (ZD), and
celecoxib-treated (celeco) Gan mice relative to that
of control Gan (cont) mice (mean ± SD). Asterisks
indicate P < 0.05.which causes EGFR activation.(12,15) However, the present
results indicate that the expression of ADAM8, ADAM9,
ADAM10, ADAM17, and ADAM28 are induced in gastric
tumors in a PGE2 pathway-dependent manner. Although we
could not find direct induction of these ADAMs by PGE2 in epi-
thelial cells or macrophages, it is possible that PGE2-associated
inflammation induces these ADAMs indirectly. It has consis-
tently been shown that the inflammatory cytokine IL-8 induces
ADAM10-dependent shedding of HB-EGF and amphiregu-
lin.(33) Notably, all of these induced ADAMs have been shown
to be important in tumorigenesis.(27) In addition to shedding of
EGFR ligands, they induce tumor cell migration, invasion and
dissemination.(27,34,35) Therefore, it is conceivable that induction
of such ADAM functions by activated PGE2 pathway contrib-
utes to gastric tumorigenesis and malignant progression.
To examine the role of macrophages for induction of EGFR
ligands and ADAMs, we used RAW264 mouse macrophage cell
line because it was technically difficult to prepare macrophages
from the in vivo gastric tumors. Therefore, it remains to be con-
firmed the induction of EGFR ligands and ADAMs in the
tumor-infiltrated macrophages.
Helicobacter pylori infection induces expression of HB-EGF
and amphiregulin in gastric cancer cells.(36–38) H. pylori infec-
tion in mice carrying the kinase-defective mutant EGFR allele
(EGFRwa2) showed increased apoptosis of gastric epithelial
cells, suggesting that EGFR activation by H. pylori infection is
important for protection from apoptosis.(39) Moreover, H. pylori
infection to Adam17-disrupted gastric epithelial cells failed to
activate the EGFR, suggesting that ADAMs play a role in
H. pylori infection-induced EGFR activation.(39) Importantly,
we previously showed that H. felis infection caused induction of
Ptgs2 and Ptges in gastric epithelial cells.(16)
Accordingly, it is possible that H. pylori infection induces
PGE2 pathway, which further activates EGFR through global
induction of EGFR ligands and ADAMs, similar to the effects718observed in the C2mE group mice. It is therefore possible that
inhibition of the PGE2 pathway, as well as eradication of
H. pylori infection, can suppress EGFR activation in the
H. pylori-infected gastric mucosa, thereby preventing gastric
carcinogenesis.
The level of PGE2 is regulated by 15-hydroxyprostaglandin
dehydrogenase (15-PGDH), which inactivates prostaglandins.
Importantly, expression of 15-PGDH is downregulated by
EGFR signaling in colon cancer cells,(40) indicating that EGFR
signaling activates PGE2 pathway. Moreover, disruption of the
15-PGDH gene accelerates intestinal tumorigenesis in mouse
models.(41) Accordingly, it is possible that inhibition of both
PGE2 and EGFR pathways represents an effective therapeutic
strategy for gastrointestinal tumorigenesis by suppression of
both the individual signaling pathways and the positive feedback
loop between two signaling pathways. Among the four PGE2
receptors, EP4 is the most abundant receptor in mouse gastric
tumor models(24) and in human colon cancer tissues.(42) We have
shown here that EP4 signaling is responsible for global induc-
tion of EGFR ligands and ADAMs through direct or indirect
mechanisms, and macrophages are major source of EGFR
ligands. Moreover, we have recently demonstrated that inhibi-
tion of EP4 signaling significantly suppressed gastric tumorigen-
esis in Gan mice.(43) These results, taken together, suggest that
combination treatment with inhibitors of EGFR and EP4 will be
an effective strategy for preventing gastric tumorigenesis.
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